Get started
Author

Brian Steingo

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
2018 · Ludwig Kappos, Amit Bar-Or, et al. · The Lancet · 970
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
2021 · Daniel S Reich, Douglas L Arnold, et al. · The Lancet Neurology · 210
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
2022 · John F Foley, Gilles Defer, et al. · The Lancet Neurology · 121
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS
2016 · Robert J. Fox, Andrew Chan, et al. · Neurology Clinical Practice · 105
PDF
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
2015 · David H. Miller, Robert J. Fox, et al. · Neurology · 66
PDF
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
2016 · Gavin Giovannoni, Jeffrey A. Cohen, et al. · Neurology · 64
PDF
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
2020 · Brian Steingo, Yaser Al Malik, et al. · Journal of Neurology · 56
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
2019 · Adam Cuker, Ann D Bass, et al. · Multiple Sclerosis Journal · 53
PDF
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial
2014 · Jonathan Calkwood, Bruce Cree, et al. · BMC Neurology · 38
PDF
CLIPPERS complicating multiple sclerosis causing concerns of CNS lymphoma
2012 · Melissa R. Ortega, Nida Usmani, et al. · Neurology · 34
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
2019 · Bart Van Wijmeersch, Barry A Singer, et al. · Multiple Sclerosis Journal · 20
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
2019 · Annette F. Okai, Lilyana Amezcua, et al. · Neurology and Therapy · 11
PDF
Satralizumab treatment in patients with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series
2025 · Hesham Abboud, Brian Steingo, et al. · Journal of Neuroimmunology · 8
PDF
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
2015 · Bjorn Tackenberg, Tjalf Ziemssen, et al. · Neurology · 7
PDF
Huntington's disease in a Coloured family.
1974 · D S Saffer, D C Nathan, et al. · PubMed · 6
Immune response to influenza vaccine in patients with relapsing multiple sclerosis treated with ofatumumab: Results from an open-label, multicenter, phase 4 study
2025 · Brian Steingo, Adnan Subei, et al. · Multiple Sclerosis and Related Disorders · 3
PDF
Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice
2025 · Hesham Abboud, Brian Steingo, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 1
Pneumonitis as an early complication of alemtuzumab treatment (P5.406)
2017 · Daniel Kantor, Brian Steingo · Neurology · 1
Real-World Patient Retention and Satisfaction on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS (P6.167)
2016 · Heidi Crayton, Brian Steingo, et al. · Neurology · 1
The diagnosis and significance of isolated third nerve palsy in the African.
1977 · D Saffer, B Steingo, et al. · PubMed · 1
Satralizumab Treatment in Adult Patients With AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series (P13-5.010)
2023 · Hesham Abboud, Brian Steingo, et al. · Neurology
7-Year Outcomes in MS Patients of African Descent Treated With Alemtuzumab: Follow-up of CARE-MS I and II (TOPAZ study) (P3.2-067)
2019 · Mitzi Williams, Lilyana Amezcua, et al. · Neurology
A.03 Durable clinical and MRI efficacy of alemtuzumab over 6 years in CARE-MS II patients with RRMS who relapsed between Courses 1 and 2
2018 · MS Freedman, S Broadley, et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
PDF
Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (P6.366)
2018 · Brian Steingo, Celia Oreja-Guevara, et al. · Neurology
Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)
2018 · Brian Steingo, Celia Oreja‐Guevara, et al. · Document Server@UHasselt (UHasselt)
Works count: 35
Citation count: 1,777
H-index: 11
I10-index: 12
Year
Topic
Type